
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31156478</article-id><article-id pub-id-type="pmc">6529840</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2019.00330</article-id><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Brief Research Report</subject></subj-group></subj-group></article-categories><title-group><article-title>Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Masopust</surname><given-names>Jiri</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/590718"/></contrib><contrib contrib-type="author"><name><surname>Bazantova</surname><given-names>Vera</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kuca</surname><given-names>Kamil</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/143543"/></contrib><contrib contrib-type="author"><name><surname>Klimova</surname><given-names>Blanka</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/338430"/></contrib><contrib contrib-type="author"><name><surname>Valis</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff1">
<sup>1</sup><institution>Department of Psychiatry, Charles University in Prague, Faculty of Medicine in Hradec Kralove and University Hospital</institution>, <addr-line>Hradec Kralove</addr-line>, <country>Czechia</country></aff><aff id="aff2">
<sup>2</sup><institution>Department of Neurology, Charles University in Prague, Faculty of Medicine in Hradec Kralove and University Hospital</institution>, <addr-line>Hradec Kralove</addr-line>, <country>Czechia</country></aff><aff id="aff3">
<sup>3</sup><institution>Department of Chemistry, Faculty of Science, University of Hradec Kralove</institution>, <addr-line>Hradec Kralove</addr-line>, <country>Czechia</country></aff><aff id="aff4">
<sup>4</sup><institution>Biomedical Research Center, University Hospital Hradec Kralove</institution>, <addr-line>Hradec Kralove</addr-line>, <country>Czechia</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Mirko Manchia, University of Cagliari, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Martino Belvederi Murri, University of Genoa, Italy; Luca Steardo, University Magna Graecia of Catanzaro, Italy</p></fn><corresp id="fn001">*Correspondence: Kamil Kuca, <email xlink:href="mailto:kamil.kuca@uhk.cz" xlink:type="simple">kamil.kuca@uhk.cz</email>
</corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>330</elocation-id><history><date date-type="received"><day>21</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Masopust, Bazantova, Kuca, Klimova and Valis</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Masopust, Bazantova, Kuca, Klimova and Valis</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>
<bold>Objective:</bold> Venous thromboembolism (VTE) is a serious multifactorial disorder. Patients with severe mental illness have a higher risk of developing the condition compared to the general population.</p><p>
<bold>Methods:</bold> We observed 10 cases of VTE in patients with mental illness who were treated with the antipsychotic drug olanzapine. The diagnosis of VTE was made at the University Hospital Hradec Kralove (UH HK) from 2004 to 2013. VTE was objectively determined by imaging techniques (duplex ultrasonography, CT angiography) and laboratory tests (D-dimer). The average age was 46 years. The clinical manifestation of VTE was deep vein thrombosis in nine cases, including one case of simultaneous pulmonary embolism and one case of a concurrent ischemic cerebrovascular accident (iCVA). None of our patients had a history of malignant disease, trauma, or surgery.</p><p>
<bold>Results:</bold> Apart from antipsychotic medication, all the patients had clinical or laboratory risk factors for VTE. The most frequent clinical risk factors were obesity (n = 7) and smoking (n = 6). The most frequent laboratory risk factors were increased levels of FVIII (n = 4), mild hyperhomocysteinemia (n = 3), and factor V Leiden mutation (n = 2). VTE developed within 3 months after antipsychotic drug initiation in three patients and within 6 months in three patients.</p><p>
<bold>Conclusion:</bold> Olanzapine can be considered a precipitating factor for VTE formation. When olanzapine is administered, we need to monitor for clinical signs and symptoms of VTE, especially when other risk factors are present.</p></abstract><kwd-group><kwd>antipsychotics</kwd><kwd>olanzapine</kwd><kwd>venous thromboembolism</kwd><kwd>side effects</kwd><kwd>risk factors</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Univerzita Karlova v Praze<named-content content-type="fundref-id">10.13039/100007397</named-content></funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="2"/><equation-count count="0"/><ref-count count="26"/><page-count count="6"/><word-count count="2620"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Venous thromboembolism (VTE) is a serious and potentially life-threatening condition. Manifestations of VTE include deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is associated with high morbidity and mortality. Considerable amounts of money are also spent on the treatment of VTE in the developed countries of Europe and North America. VTE affects approximately 1.0&#x02013;1.8 people per 1,000 annually (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). The incidence rises exponentially with age, and the risk significantly increases in people over the age of 40 years (<xref rid="B3" ref-type="bibr">3</xref>). Multiple risk factors are involved in the development of VTE. VTE risk factors can be divided into physiological and pathophysiological, clinical and laboratory, and congenital and acquired factors (<xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>) (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Risk factors for VTE [adapted from Refs. (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>)].</p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" rowspan="5" colspan="1">Congenital</td><td valign="top" rowspan="1" colspan="1">Antithrombin deficiency</td></tr><tr><td valign="top" rowspan="1" colspan="1">Protein C deficiency</td></tr><tr><td valign="top" rowspan="1" colspan="1">Protein S deficiency</td></tr><tr><td valign="top" rowspan="1" colspan="1">Factor V Leiden mutation</td></tr><tr><td valign="top" rowspan="1" colspan="1">Factor II mutation</td></tr><tr><td valign="top" rowspan="8" colspan="1">Acquired</td><td valign="top" rowspan="1" colspan="1">Increasing age</td></tr><tr><td valign="top" rowspan="1" colspan="1">Malignancy</td></tr><tr><td valign="top" rowspan="1" colspan="1">Antiphospholipid syndrome</td></tr><tr><td valign="top" rowspan="1" colspan="1">Inflammatory bowel disease</td></tr><tr><td valign="top" rowspan="1" colspan="1">Systemic lupus erythematosus</td></tr><tr><td valign="top" rowspan="1" colspan="1">Nephrotic syndrome</td></tr><tr><td valign="top" rowspan="1" colspan="1">Overweight and obesity</td></tr><tr><td valign="top" rowspan="1" colspan="1">Microalbuminuria</td></tr><tr><td valign="top" rowspan="7" colspan="1">External</td><td valign="top" rowspan="1" colspan="1">Infectious disease</td></tr><tr><td valign="top" rowspan="1" colspan="1">Surgery, trauma, immobilization</td></tr><tr><td valign="top" rowspan="1" colspan="1">Pregnancy and puerperium</td></tr><tr><td valign="top" rowspan="1" colspan="1">Oral contraceptives</td></tr><tr><td valign="top" rowspan="1" colspan="1">Hormonal replacement therapy</td></tr><tr><td valign="top" rowspan="1" colspan="1">Antipsychotic drugs</td></tr><tr><td valign="top" rowspan="1" colspan="1">Air transport (long haul)</td></tr><tr><td valign="top" rowspan="6" colspan="1">Mixed</td><td valign="top" rowspan="1" colspan="1">High factor VIII levels</td></tr><tr><td valign="top" rowspan="1" colspan="1">APC resistance</td></tr><tr><td valign="top" rowspan="1" colspan="1">Hyperhomocysteinemia</td></tr><tr><td valign="top" rowspan="1" colspan="1">High factor IX levels</td></tr><tr><td valign="top" rowspan="1" colspan="1">High factor XI levels</td></tr><tr><td valign="top" rowspan="1" colspan="1">Fibrinolysis abnormalities</td></tr><tr><td valign="top" rowspan="4" colspan="1">Partially confirmed</td><td valign="top" rowspan="1" colspan="1">High CRP levels</td></tr><tr><td valign="top" rowspan="1" colspan="1">Smoking</td></tr><tr><td valign="top" rowspan="1" colspan="1">Dyslipidemia</td></tr><tr><td valign="top" rowspan="1" colspan="1">Male sex</td></tr></tbody></table><table-wrap-foot><p>VTE, venous thromboembolism; CRP, C-Reactive Protein.</p></table-wrap-foot></table-wrap><p>The congenital risk factors for VTE have varying clinical implications for the patient as they confer different degrees of relative risk for VTE development. The risk of thrombosis rises significantly when multiple factors occur together. In older patients, acquired risk factors occur more frequently, which explains the significantly increased incidence of VTE in the elderly population.</p><p>The pathophysiological mechanism underlying VTE formation is the development of a relative thrombophilic state. This involves a shift in the hemostatic system towards thrombosis. If a genetic disposition is prominent in the etiopathogenesis of VTE, patients are determined to have hereditary thrombophilia. If external risk factors prevail, the condition is determined to be an acquired hypercoagulable state. A hypercoagulable state may result from the presence of any of the conditions belonging to the so-called Virchow triad (venous stasis, hypercoagulability, and vessel wall damage) (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>).</p><p>In patients with a mental illness, the risk of VTE is increased for several reasons. In a previous study, we found significantly increased activation of markers of thrombogenesis (sP-selectin, D-dimer, FVIII) in untreated patients experiencing a first episode of psychosis compared to healthy volunteers (<xref rid="B5" ref-type="bibr">5</xref>). The markers of thrombogenesis continued to be elevated after 1 year of treatment (<xref rid="B6" ref-type="bibr">6</xref>). Antiphospholipid antibodies (APAs), especially anticardiolipin antibodies (ACLAs), may serve as a marker of autoimmune reactivity, or they may directly interfere with phospholipid metabolism in schizophrenia patients. They may also have prothrombogenic effects. Inflammatory markers are also elevated during acute psychosis, which may lead to an increased risk of pathological blood coagulation (<xref rid="B7" ref-type="bibr">7</xref>). Hyperhomocysteinemia, which is also a risk factor for VTE, can occur in patients with mental disorders who also smoke, have poor dietary habits, and consume excessive amounts of coffee</p><p>Antipsychotic medications are another risk factor for VTE in patients with a psychotic disease (<xref rid="B8" ref-type="bibr">8</xref>). Antipsychotic drugs contribute to the development of a hypercoagulable state through several potential mechanisms, including drug-induced sedation, obesity, hyperprolactinemia, increased platelet aggregation, and elevation of APA (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B9" ref-type="bibr">9</xref>).</p><p>According to a meta-analysis by Barbui et al. (<xref rid="B10" ref-type="bibr">10</xref>), exposure to antipsychotic treatment results in a 50% increased risk for VTE. In another meta-analysis, the low-potency antipsychotic agents had the highest odds of VTE (OR 2.91; 95% CI 1.81&#x02013;4.71), followed by second-generation antipsychotics (OR 2.20; 95% CI 1.22&#x02013;3.96) and then the traditional neuroleptics (OR 1.72; 95% CI 1.31&#x02013;2.24) (<xref rid="B11" ref-type="bibr">11</xref>). The highest risk of VTE emerges during the first 3 months after initiation of antipsychotic treatment (<xref rid="B12" ref-type="bibr">12</xref>). Other studies found the highest risk in the first month after the initiation of an antipsychotic (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). In addition to the time period following drug administration and the antipsychotic drug class used, other risk factors include using higher drug doses, using a combination of several antipsychotic drugs, and parenteral administration of antipsychotic agents (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Through a long-term project named ANTRE (ANTipsychotics, ThRombosis, Embolism) involving interdisciplinary cooperation within the University Hospital in Hradec Kralove, we have been aiming to develop a comprehensive approach to the issue of VTE in patients treated with antipsychotic drugs. Cases of VTE development are carefully recorded. In addition to isolated case reports of VTE development during treatment with different antipsychotic agents, we recorded 10 cases involving the administration of olanzapine.</p></sec><sec id="s2"><title>Patients and Methods</title><p>The patient group consisted of a total of 10 patients (women n = 3) who were treated with olanzapine. VTE occurrence was monitored prospectively between 2004 and 2013 in a specialized outpatient unit for VTE treatment. The average age of the patients was 46 years, with a range of 17 to 71 years. Three patients had a diagnosis of delusional disorder, two had paranoid schizophrenia, and two had bipolar disorder. The other patient diagnoses were an addiction to multiple narcotic drugs, behavioral disorder related to pregnancy and puerperium, and mental retardation with a behavioral disorder. The duration of psychiatric illness prior to the occurrence of VTE was determined. We also determined the duration and dose of olanzapine utilized prior to VTE and recorded other psychotropic drugs taken concomitantly. Information was collected from patient-reported history, the hospital information system, and reports by attending outpatient psychiatrists. None of the patients had previously suffered from VTE. Patient history was used to determine if there was a family history (FH) of VTE. In the patient group, VTE occurred either during hospitalization or during outpatient care. VTE diagnosis and subsequent treatment were conducted by an internist. If clinical symptoms suggested VTE, then additional examinations were conducted. In all cases, VTE was verified using imaging techniques (duplex ultrasonography, CT angiography) and laboratory methods (D-dimer). Blood tests were used to detect laboratory risk factors. All laboratory tests were conducted in the same laboratory.</p><p>Due to the case study nature of the data, we mostly used methods of descriptive statistics. Frequencies for sex, clinical and laboratory risk factors, smoking, and VTE together with averages for age, weight gain, dose of olanzapine, and length of use were calculated. A paired-sample t-test was used for weight gain.</p></sec><sec sec-type="results" id="s3"><title>Results</title><p>VTE manifested clinically as DVT in the lower limbs in nine patients. In one of these patients, PE also developed at the same time. In one patient, VTE manifested clinically as neurological symptoms without symptoms of DVT. These atypical symptoms were due to a paradoxical embolization in the setting of a heart malformation, patent foramen ovale. Clinical or laboratory risk factors for VTE development were present in all the patients. The most frequent clinical risk factors were obesity (n = 7) and smoking (n = 6). The most frequent laboratory risk factors were elevated FVIII level (n = 4) and mild homocysteinemia (HCY) (n = 3). In these patients, mild HCY was always present together with elevated FVIII level. FV Leiden mutation was detected in two patients. Both clinical and laboratory risk factors were present in half (n = 5) of the patients. Positive FH for VTE was found in three patients. In one case, VTE resulted in the death of an affected family member. In six patients, VTE developed within 6 months of olanzapine initiation, and within 3 months in three patients. VTE developed during hospitalization in three cases. The average dose of olanzapine was 14.5&#x02009;mg daily, and the average length of use was 14 months prior to VTE. Only one patient was using olanzapine monotherapy. There was also statistically significant weight gain recorded during treatment with olanzapine (p = 0.031). The results are summarized in <xref rid="T2" ref-type="table">
<bold>Table 2</bold>
</xref>.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Characteristics of the patient group, including demography, diagnosis, duration of illness, dose and time of olanzapine use, adjuvant medication, and BMI before olanzapine initiation and during VTE development.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="2" colspan="1"/><th valign="top" rowspan="2" colspan="1">Sex (age range)</th><th valign="top" rowspan="2" colspan="1">Diagnosis (years of illness)</th><th valign="top" colspan="2" align="center" rowspan="1">Psychotropic drugs</th><th valign="top" rowspan="2" colspan="1">BMI before/after OLA treatment</th><th valign="top" colspan="2" align="center" rowspan="1">VTE risk factors</th><th valign="top" colspan="3" align="center" rowspan="1">VTE</th></tr><tr><th valign="top" rowspan="1" colspan="1">OLA in mg (months of use)</th><th valign="top" rowspan="1" colspan="1">Other (mg)</th><th valign="top" rowspan="1" colspan="1">clinical</th><th valign="top" rowspan="1" colspan="1">laboratory</th><th valign="top" rowspan="1" colspan="1">PH</th><th valign="top" rowspan="1" colspan="1">FH</th><th valign="top" rowspan="1" colspan="1">Therapy</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">
<bold>1</bold>
</td><td valign="top" rowspan="1" colspan="1">Male<break/>(51&#x02013;55)</td><td valign="top" rowspan="1" colspan="1">F22 (24)</td><td valign="top" rowspan="1" colspan="1">5 (2)</td><td valign="top" rowspan="1" colspan="1">alprazolam 1</td><td valign="top" rowspan="1" colspan="1">26.4/27.6</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">mild HCY<break/>elevated FVIII</td><td valign="top" rowspan="1" colspan="1">DVT<break/>PE</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">LMWH<break/>warfarin</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>2</bold>
</td><td valign="top" rowspan="1" colspan="1">Male<break/>(51&#x02013;55)</td><td valign="top" rowspan="1" colspan="1">F22 (0.5)</td><td valign="top" rowspan="1" colspan="1">10 (6)</td><td valign="top" rowspan="1" colspan="1">sertraline 100</td><td valign="top" rowspan="1" colspan="1">23.7/23.7</td><td valign="top" rowspan="1" colspan="1">smoking</td><td valign="top" rowspan="1" colspan="1">FII mutation (het)</td><td valign="top" rowspan="1" colspan="1">DVT</td><td valign="top" rowspan="1" colspan="1">+</td><td valign="top" rowspan="1" colspan="1">LMWH<break/>warfarin</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>3</bold>
</td><td valign="top" rowspan="1" colspan="1">Male<break/>(36&#x02013;40)</td><td valign="top" rowspan="1" colspan="1">F20 (10)</td><td valign="top" rowspan="1" colspan="1">10 (6)</td><td valign="top" rowspan="1" colspan="1">zotepine 100<break/>levomepromazine 25</td><td valign="top" rowspan="1" colspan="1">30/34</td><td valign="top" rowspan="1" colspan="1">obesity<break/>smoking</td><td valign="top" rowspan="1" colspan="1">FV Leiden mutation (het)</td><td valign="top" rowspan="1" colspan="1">DVT</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">LMWH<break/>warfarin<break/>alteplase<break/>SCF</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>4</bold>
</td><td valign="top" rowspan="1" colspan="1">Female<break/>(51&#x02013;55)</td><td valign="top" rowspan="1" colspan="1">F22 (32)</td><td valign="top" rowspan="1" colspan="1">20 (17)</td><td valign="top" rowspan="1" colspan="1">citalopram 40<break/>oxazepam 15</td><td valign="top" rowspan="1" colspan="1">29.7/30.9</td><td valign="top" rowspan="1" colspan="1">obesity<break/>smoking<break/>immobilization</td><td valign="top" rowspan="1" colspan="1">mild HCY<break/>elevated FVIII</td><td valign="top" rowspan="1" colspan="1">DVT</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">LMWH<break/>warfarin</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>5</bold>
</td><td valign="top" rowspan="1" colspan="1">Female<break/>(71&#x02013;75)</td><td valign="top" rowspan="1" colspan="1">F31 (19)</td><td valign="top" rowspan="1" colspan="1">20 (6)</td><td valign="top" rowspan="1" colspan="1">escitalopram 10<break/>trazodone 150<break/>oxazepam 15<break/>lamotrigine 25</td><td valign="top" rowspan="1" colspan="1">29.8/30.8</td><td valign="top" rowspan="1" colspan="1">obesity<break/>LE varicose veins<break/>immobilization</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">DVT</td><td valign="top" rowspan="1" colspan="1">+</td><td valign="top" rowspan="1" colspan="1">LMWH<break/>warfarin</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" rowspan="1" colspan="1">Male<break/>(56&#x02013;60)</td><td valign="top" rowspan="1" colspan="1">F19.2 (10)</td><td valign="top" rowspan="1" colspan="1">10 (12)</td><td valign="top" rowspan="1" colspan="1">clonazepam 5<break/>promethazine 50</td><td valign="top" rowspan="1" colspan="1">30.9/30</td><td valign="top" rowspan="1" colspan="1">obesity<break/>smoking</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">DVT</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">LMWH<break/>warfarin</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>7</bold>
</td><td valign="top" rowspan="1" colspan="1">Female<break/>(31&#x02013;35)</td><td valign="top" rowspan="1" colspan="1">F53.1 (0.2)</td><td valign="top" rowspan="1" colspan="1">20 (0.17)</td><td valign="top" rowspan="1" colspan="1">venlafaxine 225</td><td valign="top" rowspan="1" colspan="1">28.2/32.6</td><td valign="top" rowspan="1" colspan="1">obesity<break/>immobilization<break/>puerperium</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">DVT</td><td valign="top" rowspan="1" colspan="1">+</td><td valign="top" rowspan="1" colspan="1">LMWH<break/>warfarin</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>8</bold>
</td><td valign="top" rowspan="1" colspan="1">Male<break/>(36&#x02013;40)</td><td valign="top" rowspan="1" colspan="1">F20 (13)</td><td valign="top" rowspan="1" colspan="1">30 (84)</td><td valign="top" rowspan="1" colspan="1">clonazepam 1</td><td valign="top" rowspan="1" colspan="1">28/28.6</td><td valign="top" rowspan="1" colspan="1">smoking</td><td valign="top" rowspan="1" colspan="1">elevated FVIII</td><td valign="top" rowspan="1" colspan="1">DVT</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">warfarin</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>9</bold>
</td><td valign="top" rowspan="1" colspan="1">Male<break/>(15&#x02013;19)</td><td valign="top" rowspan="1" colspan="1">F72.1 (17)</td><td valign="top" rowspan="1" colspan="1">10 (1)</td><td valign="top" rowspan="1" colspan="1">levomepromazine 125<break/>chlorprothixene 250<break/>
</td><td valign="top" rowspan="1" colspan="1">25.2/31.7</td><td valign="top" rowspan="1" colspan="1">obesity</td><td valign="top" rowspan="1" colspan="1">FV Leiden mutation (het)<break/>elevated FVIII<break/>mild HCY</td><td valign="top" rowspan="1" colspan="1">DVT</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">LMWH<break/>warfarin</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<bold>10</bold>
</td><td valign="top" rowspan="1" colspan="1">Male<break/>(41&#x02013;45)</td><td valign="top" rowspan="1" colspan="1">F30.2 (0.7)</td><td valign="top" rowspan="1" colspan="1">10 (3.5)</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">31.7/30.5</td><td valign="top" rowspan="1" colspan="1">obesity<break/>smoking<break/>LE varicose veins</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">paradoxical embolization</td><td valign="top" rowspan="1" colspan="1">&#x02212;</td><td valign="top" rowspan="1" colspan="1">ac. acetylsalicylicum<break/>occluder implantation</td></tr></tbody></table><table-wrap-foot><p>OLA, olanzapine; BMI, body mass index; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; iCVA, ischemic cerebrovascular accident; LE, lower extremities; HCY, homocysteinemia; het, heterozygote; PH, personal history; FH, family history; LWMH, low-molecular-weight heparin; SCF, subrenal cava filter.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Olanzapine is a widely used, affordable, and effective second-generation antipsychotic drug. It is indicated for the treatment of schizophrenia and bipolar disorder. In clinical practice, the spectrum of its use is much wider. Off-label indications include psychotic disorders of various etiologies (toxic and organic), behavioral disorders in patients with dementia, eating disorders, and personality disorders. The relatively high incidence of olanzapine-related VTE may be distorted by the high number of patients treated with this antipsychotic agent.</p><p>A possible prothrombogenic mechanism of olanzapine at the molecular level is an affinity for 5-HT<sub>2A</sub> serotonin receptors. Blocking these receptors results in increased platelet aggregation and increased blood coagulability (<xref rid="B16" ref-type="bibr">16</xref>). Blockade of &#x003b1;<sub>1</sub> adrenergic receptors by olanzapine may cause hypotension and thereby venous stasis in the lower limbs. Another mechanism may be olanzapine-induced production of the antiphospholipid antibodies: lupus anticoagulant (LA) and ACLAs (<xref rid="B17" ref-type="bibr">17</xref>). Increasing these APA titers is associated with a prothrombogenic state (<xref rid="B18" ref-type="bibr">18</xref>). Olanzapine may also induce a temporary increase in prolactin levels early in the course of treatment. Hyperprolactinemia correlates with increased levels of P-selectin, a platelet activation marker (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>Metabolic symptoms caused by olanzapine represent an indirect mechanism for VTE development. The prothrombogenic metabolic symptoms that often occur during olanzapine treatment include hyperglycemia, hyperleptinemia, dyslipidemia, and weight gain (<xref rid="B20" ref-type="bibr">20</xref>). Weight gain is mainly due to the blockade of H<sub>1</sub> histamine and 5-HT<sub>2C</sub> serotonin receptors by olanzapine.</p><p>Obesity [body mass index (BMI) &#x02265; 30)] is associated with an up to two-fold increase in the risk of VTE development. Obese patients have reduced fibrinolytic activity and capacity. Higher levels of the procoagulation factors FVIII and FIX also occur (<xref rid="B21" ref-type="bibr">21</xref>). Central obesity is also accompanied by a procoagulant and hypofibrinolytic state related to inflammation, oxidative stress, dyslipidemia, and ectopic fat deposition (<xref rid="B22" ref-type="bibr">22</xref>). In our group, obesity was identified in seven patients. The patients&#x02019; body weight increased significantly during olanzapine treatment.</p><p>Another indirect risk factor associated with olanzapine is sedation, which reduces physical activity, leading to a reduction in blood flow. Venous stasis, which is one of the factors from the Virchow triad, increases the risk of VTE. The level of sedation in our patients could also have been potentiated by adjuvant medication. In 50% (n = 5), benzodiazepines were administered together with olanzapine. In 20% (n = 2), the sedating antipsychotic agent levomepromazine was used with olanzapine.</p><p>The risk of VTE development increases significantly during prolonged hospitalization. Patients with a mental disorder require hospitalization frequently and repeatedly. In our group, VTE occurred during hospitalization in three patients. During hospitalization, a general reduction in physical activity occurs, and sedatives are often administered at higher doses compared to outpatient treatment. Some patients also require physical restraint. During physical restraint, such as strapping the patient to a bed, injury or compression of a limb may occur. Venostasis and vascular endothelium damage can also occur, which increases the risk for VTE (<xref rid="B23" ref-type="bibr">23</xref>). In our group, physical restraint was used in only one patient.</p><p>Literature reports that the risk of VTE is highest in the first 3 months after initiation of antipsychotic treatment. This finding was confirmed in 30% of patients in our group; however, in 60%, VTE developed within 6 months after olanzapine initiation. Our findings confirm those of other studies, which found that the highest risk of VTE development exists in the early stages of antipsychotic treatment (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>FV Leiden mutation is the most frequently occurring laboratory risk factor for VTE development in the general population (<xref rid="B1" ref-type="bibr">1</xref>). It can be detected in 20&#x02013;25% of patients with a diagnosis of VTE. This corresponds with the findings from our group, in which FV Leiden mutation was identified in 20% (n = 2) of the cases.</p><p>This is the largest group of patients with VTE occurrence during olanzapine treatment ever described in the literature. The merits of our work include meticulous VTE diagnosis using modern imaging methods and laboratory testing. The number of VTE cases reported during treatment with olanzapine may be influenced by the fact that it is a very frequently used antipsychotic drug.</p><p>Antipsychotic agents, in general, may be regarded as one risk factor for VTE development. Patients with psychosis have a higher incidence of cardiovascular risk factors (obesity, diabetes mellitus, arterial hypertension, dyslipidemia, and smoking) that are also associated with a higher risk for VTE development (<xref rid="B25" ref-type="bibr">25</xref>). In VTE pathogenesis, it is difficult to differentiate between the role of the underlying psychiatric condition, hospitalization or physical restraint, and the action of antipsychotic drugs. The precise biological mechanisms of increased VTE during antipsychotic use remain unclear.</p><p>When selecting particular treatment, the presence of VTE risk factors should be considered for every patient. Treatments should be selected only if they do not further increase the risk. During antipsychotic therapy, the risk for VTE development needs to be monitored, and prophylactic measures should be initiated in a timely manner. Diagnosing VTE in mentally ill patients may be more difficult than in the general population. High-risk patients treated with antipsychotic drugs should receive clear information on the possible adverse effects of the treatment, including clinical signs and symptoms of venous thrombosis and PE, and on the necessity of seeking medical attention if such symptoms occur.</p><p>In hospitalized immobilized psychiatric patients, the degree of VTE risk needs to be determined so that preventive measures can be taken (<xref rid="B26" ref-type="bibr">26</xref>). Whenever clinical symptoms of VTE occur, the diagnosis needs to be confirmed or ruled out immediately by imaging and laboratory tests.</p><p>Further prospective studies are needed to shed more light on the relationship between VTE and antipsychotic agents, focusing on risk quantification for the individual antipsychotic drugs, and to elucidate the basic biological mechanisms.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>We have described 10 patients with VTE occurrence during treatment with olanzapine. In all the cases, additional clinical or laboratory risk factors were detected. Olanzapine can be considered a precipitating factor for VTE development. During olanzapine administration, patients need to be monitored for clinical signs of VTE, particularly when multiple risk factors are present.</p></sec><sec sec-type="data-availability" id="s6"><title>Data Availability Statement</title><p>The data sets generated and/or analyzed during the current study are available from the authors.</p></sec><sec id="s7"><title>Ethics Statement</title><p>This study was approved by the ethical committee of FNHK (Hradec Kralove, Czechia). Informed consent was obtained from all individual participants included in the study.</p></sec><sec id="s8"><title>Author Contributions</title><p>MV, JM, and VB contributed to the data collection. MV, JM, BK, and KK contributed to the preparation of the draft.</p></sec><sec sec-type="funding-information" id="s9"><title>Funding</title><p>This paper was supported by the research project PROGRES Q40 at the Medical Faculty of Charles University and by MH CZ&#x02013;DRO (UHHK 00179906). It was also supported by the long-term development plan of UHK.</p></sec><sec id="s10"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Nisio</surname><given-names>M</given-names></name><name><surname>van Es</surname><given-names>N</given-names></name><name><surname>Buller</surname><given-names>HR</given-names></name></person-group>
<article-title>Deep vein thrombosis and pulmonary embolism</article-title>. <source>Lancet</source> (<year>2016</year>) <volume>388</volume>:<page-range>3060&#x02013;73</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)30514-1</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heit</surname><given-names>JA</given-names></name><name><surname>Spencer</surname><given-names>FA</given-names></name><name><surname>White</surname><given-names>RH</given-names></name></person-group>
<article-title>The epidemiology of venous thromboembolism</article-title>. <source>J Thromb Thrombolysis</source> (<year>2016</year>) <volume>41</volume>:<fpage>3</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/s11239-015-1311-6</pub-id>
<pub-id pub-id-type="pmid">26780736</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AT</given-names></name><name><surname>Agnelli</surname><given-names>G</given-names></name><name><surname>Anderson</surname><given-names>FA</given-names></name><name><surname>Arcelus</surname><given-names>JI</given-names></name><name><surname>Berqvist</surname><given-names>D</given-names></name><name><surname>Brecht</surname><given-names>JG</given-names></name><etal/></person-group>
<article-title>Venous thromboembolism (VTE) in Europe</article-title>. <source>Thromb Haemost</source> (<year>2007</year>) <volume>98</volume>:<page-range>756&#x02013;64</page-range>. <pub-id pub-id-type="doi">10.1160/TH07-03-0212</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lijfering</surname><given-names>WM</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Cannegieter</surname><given-names>SC</given-names></name></person-group>
<article-title>Risk factors for venous thrombosis&#x02014;current understanding from an epidemiological point of view</article-title>. <source>Br J Haematol</source> (<year>2010</year>) <volume>149</volume>:<page-range>824&#x02013;33</page-range>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08206.x</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masopust</surname><given-names>J</given-names></name><name><surname>Maly</surname><given-names>R</given-names></name><name><surname>Andrys</surname><given-names>C</given-names></name><name><surname>Valis</surname><given-names>M</given-names></name><name><surname>Bazant</surname><given-names>J</given-names></name><name><surname>Hosak</surname><given-names>L</given-names></name></person-group>
<article-title>Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study</article-title>. <source>BMC Psychiatry</source> (<year>2011</year>) <volume>11</volume>:<fpage>2</fpage>. <pub-id pub-id-type="doi">10.1186/1471-244X-11-2</pub-id>
<pub-id pub-id-type="pmid">21199572</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masopust</surname><given-names>J</given-names></name><name><surname>Maly</surname><given-names>R</given-names></name><name><surname>Andrys</surname><given-names>C</given-names></name><name><surname>Valis</surname><given-names>M</given-names></name><name><surname>Bazant</surname><given-names>J</given-names></name><name><surname>Hosak</surname><given-names>L</given-names></name></person-group>
<article-title>The dynamics of haemostatic parameters in acute psychotic patients: a one-year prospective study</article-title>. <source>Psychiatr Danub</source> (<year>2013</year>) <volume>25</volume>:<page-range>142&#x02013;8</page-range>.</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khandaker</surname><given-names>GM</given-names></name><name><surname>Cousins</surname><given-names>L</given-names></name><name><surname>Deakin</surname><given-names>J</given-names></name><name><surname>Lennox</surname><given-names>BR</given-names></name><name><surname>Yolken</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>PB</given-names></name></person-group>
<article-title>Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment</article-title>. <source>Lancet Psychiatry</source> (<year>2015</year>) <volume>2</volume>:<page-range>258&#x02013;70</page-range>. <pub-id pub-id-type="doi">10.1016/S2215-0366(14)00122-9</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hagg</surname><given-names>S</given-names></name><name><surname>Bate</surname><given-names>A</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Spigset</surname><given-names>O</given-names></name></person-group>
<article-title>Associations between venous thromboembolism and antipsychotics</article-title>. <source>Drug Saf</source> (<year>2008</year>) <volume>31</volume>:<page-range>685&#x02013;94</page-range>. <pub-id pub-id-type="doi">10.2165/00002018-200831080-00005</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jonsson</surname><given-names>AK</given-names></name><name><surname>Schill</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>H</given-names></name><name><surname>Spigset</surname><given-names>O</given-names></name><name><surname>Hagg</surname><given-names>S</given-names></name></person-group>
<article-title>Venous thromboembolism during treatment with antipsychotics: a review of current evidence</article-title>. <source>CNS Drugs</source> (<year>2018</year>) <volume>32</volume>:<fpage>47</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1007/s40263-018-0495-7</pub-id>
<pub-id pub-id-type="pmid">29423659</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbui</surname><given-names>C</given-names></name><name><surname>Conti</surname><given-names>V</given-names></name><name><surname>Cipriani</surname><given-names>A</given-names></name></person-group>
<article-title>Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies</article-title>. <source>Drug Saf</source> (<year>2014</year>) <volume>37</volume>:<fpage>79</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1007/s40264-013-0127-6</pub-id>
<pub-id pub-id-type="pmid">24403009</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Shao</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Ying</surname><given-names>K</given-names></name></person-group>
<article-title>Antipsychotics and venous thromboembolism risk: a meta-analysis</article-title>. <source>Pharmacopsychiatry</source> (<year>2011</year>) <volume>44</volume>:<page-range>183&#x02013;8</page-range>. <pub-id pub-id-type="doi">10.1055/s-0031-1280814</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masopust</surname><given-names>J</given-names></name><name><surname>Maly</surname><given-names>R</given-names></name><name><surname>Valis</surname><given-names>M</given-names></name></person-group>
<article-title>Risk of venous thromboembolism during treatment with antipsychotic agents</article-title>. <source>Psychiatry Clin Neurosci</source> (<year>2012</year>) <volume>66</volume>:<page-range>541&#x02013;52</page-range>. <pub-id pub-id-type="doi">10.1111/pcn.12001</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>CS</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Chang</surname><given-names>CM</given-names></name><name><surname>Wu</surname><given-names>KY</given-names></name><name><surname>Liang</surname><given-names>HY</given-names></name><name><surname>Huang</surname><given-names>YW</given-names></name><etal/></person-group>
<article-title>Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study</article-title>. <source>J Clin Psychiatry</source> (<year>2013</year>) <volume>74</volume>:<page-range>918&#x02013;24</page-range>. <pub-id pub-id-type="doi">10.4088/JCP.12m08117</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishiguro</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Jick</surname><given-names>S</given-names></name></person-group>
<article-title>Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case&#x02013;control study using the CPRD</article-title>. <source>Pharmacoepidemiol Drug Saf</source> (<year>2014</year>) <volume>23</volume>:<page-range>1168&#x02013;75</page-range>. <pub-id pub-id-type="doi">10.1002/pds.3699</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shulman</surname><given-names>M</given-names></name><name><surname>Njoku</surname><given-names>IJ</given-names></name><name><surname>Manu</surname><given-names>P</given-names></name></person-group>
<article-title>Thrombotic complications of treatment with antipsychotic drugs</article-title>. <source>Minerva Med</source> (<year>2013</year>) <volume>104</volume>:<page-range>175&#x02013;84</page-range></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kamijo</surname><given-names>Y</given-names></name><name><surname>Soma</surname><given-names>K</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Kurihara</surname><given-names>K</given-names></name><name><surname>Ohwada</surname><given-names>T</given-names></name></person-group>
<article-title>Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines</article-title>. <source>Circ J</source> (<year>2003</year>) <volume>67</volume>:<page-range>46&#x02013;8</page-range>. <pub-id pub-id-type="doi">10.1253/circj.67.46</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosendaal</surname><given-names>FR</given-names></name></person-group>
<article-title>Venous thrombosis: the role of genes, environment, and behavior</article-title>. <source>Hematol Am Soc Hematol Educ Program</source> (<year>2005</year>) <volume>2005</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1182/asheducation-2005.1.1</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhanji</surname><given-names>NH</given-names></name><name><surname>Chouinard</surname><given-names>G</given-names></name><name><surname>Hoffman</surname><given-names>L</given-names></name><name><surname>Margolese</surname><given-names>HC</given-names></name></person-group>
<article-title>Seizures, coma, and coagulopathy following olanzapine overdose</article-title>. <source>Can J Psychiatry</source> (<year>2005</year>) <volume>50</volume>:<page-range>126&#x02013;7</page-range>. <pub-id pub-id-type="doi">10.1177/070674370505000214</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wallaschofski</surname><given-names>H</given-names></name><name><surname>Eigenthaler</surname><given-names>M</given-names></name><name><surname>Kiefer</surname><given-names>M</given-names></name><name><surname>Donne</surname><given-names>M</given-names></name><name><surname>Hentschel</surname><given-names>B</given-names></name><name><surname>Gertz</surname><given-names>HJ</given-names></name><etal/></person-group>
<article-title>Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study</article-title>. <source>J Clin Psychopharmacol</source> (<year>2003</year>) <volume>23</volume>:<page-range>479&#x02013;83</page-range>. <pub-id pub-id-type="doi">10.1097/01.jcp.0000088914.24613.51</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borch</surname><given-names>KH</given-names></name><name><surname>Braekkan</surname><given-names>SK</given-names></name><name><surname>Mathiesen</surname><given-names>EB</given-names></name><name><surname>Njolstad</surname><given-names>I</given-names></name><name><surname>Wilsgaard</surname><given-names>T</given-names></name><name><surname>Stormer</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromso study</article-title>. <source>J Thromb Haemost</source> (<year>2009</year>) <volume>7</volume>:<page-range>739&#x02013;45</page-range>. <pub-id pub-id-type="doi">10.1111/j.1538-7836.2008.03234.x</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>SC</given-names></name><name><surname>Lijfering</surname><given-names>WM</given-names></name><name><surname>Naess</surname><given-names>IA</given-names></name><name><surname>Hammerstrom</surname><given-names>J</given-names></name><name><surname>van Hylckama Vlieg</surname><given-names>A</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><etal/></person-group>
<article-title>The relationship between body mass index, activated protein C resistance and risk of venous thrombosis</article-title>. <source>J Thromb Haemost</source> (<year>2012</year>) <volume>10</volume>:<page-range>1761&#x02013;7</page-range>. <pub-id pub-id-type="doi">10.1111/j.1538-7836.2012.04828.x</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morange</surname><given-names>PE</given-names></name><name><surname>Alessi</surname><given-names>MC</given-names></name></person-group>
<article-title>Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology</article-title>. <source>Thromb Haemost</source> (<year>2013</year>) <volume>110</volume>:<page-range>669&#x02013;80</page-range>. <pub-id pub-id-type="doi">10.1160/TH13-01-0075</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hem</surname><given-names>E</given-names></name><name><surname>Steen</surname><given-names>O</given-names></name><name><surname>Opjordsmoen</surname><given-names>S</given-names></name></person-group>
<article-title>Thrombosis associated with physical restraints</article-title>. <source>Acta Psychiatr Scand</source> (<year>2001</year>) <volume>103</volume>:<page-range>73&#x02013;5</page-range>. <pub-id pub-id-type="doi">10.1034/j.1600-0447.2001.00082.x</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>Coupland</surname><given-names>C</given-names></name><name><surname>Hippisley-Cox</surname><given-names>J</given-names></name></person-group>
<article-title>Antipsychotic drugs and risk of venous thromboembolism: nested case&#x02013;control study</article-title>. <source>BMJ</source> (<year>2010</year>) <volume>341</volume>:<elocation-id>c4245</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.c4245</pub-id>
<pub-id pub-id-type="pmid">20858909</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Hert</surname><given-names>M</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name><name><surname>Bobes</surname><given-names>J</given-names></name><name><surname>Cetkovich-Bakmas</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Asai</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Physical illness in patients with severe mental disorders</article-title>. <source>World Psychiatry</source> (<year>2011</year>) <volume>10</volume>:<fpage>52</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1002/j.2051-5545.2011.tb00014.x</pub-id>
<pub-id pub-id-type="pmid">21379357</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maly</surname><given-names>R</given-names></name><name><surname>Masopust</surname><given-names>J</given-names></name><name><surname>Hosak</surname><given-names>L</given-names></name><name><surname>Konupcikova</surname><given-names>K</given-names></name></person-group>
<article-title>Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients</article-title>. <source>Psychiatry Clin Neurosci</source> (<year>2008</year>) <volume>62</volume>:<fpage>3</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1819.2007.01773.x</pub-id>
<pub-id pub-id-type="pmid">18289135</pub-id></mixed-citation></ref></ref-list></back></article>